摘要
银屑病关节炎（PsA）是与银屑病相关，具有潜在致残性的炎性自身免疫病，因其易反复而迁延不愈，可致残甚至死亡，严重影响患者的生活质量。目前其治疗仍是令人困惑的问题，多数借鉴类风湿性关节炎的经验，包括传统的抗风湿药、非甾体类消炎药、糖皮质激素等。
出处
《临床内科杂志》
CAS
2009年第10期657-660,共4页
Journal of Clinical Internal Medicine
参考文献20
-
1Mease PJ, Kivitz A J, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumato1,2006 ,33 :712-721. 被引量：1
-
2de Vlam K,Lories RJ. Efficacy,effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. Rheumatology (Oxford) ,2006,45 : 321-324. 被引量：1
-
3Gottlieb AB,Kircik L,Eisen D,et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care and Treatment with Etanercept(EDUCATE) study. J Dermatolog Treat,2006,17:343-352. 被引量：1
-
4张文,赵岩,曾小峰.肿瘤坏死因子抑制剂治疗银屑病关节炎2例[J].中国实用内科杂志,2007,27(15):1213-1214. 被引量：3
-
5Haake H, Koneke J ,Amann K ,et al. Development of systemic lupus erythematosus with focal proliferative lupus nephritis during anti-TNF-alpha therapy for psoriatic arthritis. Med Klin ( Munich ), 2007, 102 : 852-857. 被引量：1
-
6Kaey S,Worm M,Audring H,et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis, 2006,65: 405 -407. 被引量：1
-
7Antoni CE, Kavanaugh A, vander Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial(IMPACT). J Rheumatol,2008 ,35:869-876. 被引量：1
-
8Kavanaugh A, Krueger GG, Beutler A, et al. lnfliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. Ann Rheum Dis,2007,66:498-505. 被引量：1
-
9Voulgari PV, Venetsanopoulou AI, Exarchou SA, et al. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study. Semin Arthritis Rheum,2008,37:293-298. 被引量：1
-
10Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis:forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum, 2007,56 : 476-488. 被引量：1
二级参考文献6
-
1Nash PT,Florin TH.Tumour necrosis factor inhibitors[J].Med J Aust,2005,183(4):205-208. 被引量：1
-
2Moreland LW,Weinblatt ME,Keystone EC,et al.Etanercept treatment in adults with established rheumatoid arthritis:7 years of clinical experience[J].J Rheum,2006,33(5):854-861. 被引量：1
-
3Mease PJ.Etanercept:a new era in the treatment of psoriatic arthritis[J].Am J Manag Care,2002,46(5):1171-1176. 被引量：1
-
4Papp KA,Tyring S,Lahfa M,et al.A global phase Ⅲ randomized controlled trial of etanercept in psoriasis:safety,efficacy,and effect of dose reduction[J].Br J Dermat,2005,152:1304-1312. 被引量：1
-
5Mease PJ,Goffe BS,Metz J,et al.Etanercept in the treatment of psoriatic arthritis and psoriasis:a randomized trial[J].Lancet,2000,356:385-390. 被引量：1
-
6Shin IS,Baer AN,Kwon HJ,et al.Guillain-Barre and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy[J].Arth Rheum,2006,54(5):1429-1434. 被引量：1
同被引文献57
-
1李先平,李晶,王皓,郭亚军.银屑病生物治疗研究进展[J].中国医药生物技术,2007,2(3):207-211. 被引量：8
-
2陆威,劳力民.关节病性银屑病发病机制及生物制剂治疗的进展[J].国外医学（皮肤性病学分册）,2005,31(6):348-351. 被引量：2
-
3张小娟,纪维,党文义,金汤.生物制剂治疗银屑病的进展[J].西北药学杂志,2007,22(3). 被引量：3
-
4王莉莎,黄烽.生物制剂在炎性关节炎中的临床应用进展[J].中国新药杂志,2007,16(15):1149-1154. 被引量：8
-
5张文,赵岩,曾小峰.肿瘤坏死因子抑制剂治疗银屑病关节炎2例[J].中国实用内科杂志,2007,27(15):1213-1214. 被引量：3
-
6Amor KT,Ryan C,Menter A.The use of cyclosporine in dermatology:PartⅠ[J].J Am Acad Dermotol,2010,63(6):925-946. 被引量：1
-
7Sfikakis PP.The first decade of biologic TNF antagonists in clinical practice:lessons learned,unresolved issues and future directions[J].Curr Dir Autoimmun,2010,11:180-210. 被引量：1
-
8Griffiths CE,Barker JN.Pathogenesis and clinical features of psoriasis[J].Lancet,2007,370(9583):263-271. 被引量：1
-
9Pasparakis M,Courtois G,Hafner M,et al.TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2[J].Nature,2002,417(6891):861-866. 被引量：1
-
10Raho G,Vena GA,Bizzoca A,et al.Influence of infliximab on keratinocyte apoptosis in psoriasis patients[J].Immunopharmacol Immunotoxicol,2011,33(1):227-231. 被引量：1
二级引证文献3
-
1陈丽.NB-UVB照射联合IL-17A抑制剂Secukinumab对寻常型银屑病患者细胞因子水平的影响[J].现代中西医结合杂志,2017,26(9):994-996. 被引量：3
-
2杨丽云,马瑞霞,聂文忠.凉血消银汤联合西药治疗急性泛发性脓疱型银屑病的临床观察[J].中国中医急症,2017,26(7):1275-1277. 被引量：17
-
3潘童,朱安礼,郭菲,李霞,关飞,李云,陈美璞.研究风湿免疫病患者应用益赛普治疗的临床疗效[J].中国实用医药,2018,13(14):103-105. 被引量：4
-
1张宏.联合用药治疗类风湿关节炎的临床分析[J].求医问药（下半月刊）,2012,10(6):78-78. 被引量：1
-
2陈鸿儒.玻璃酸钠注射液治疗膝关节骨关节炎疗效观察[J].现代中西医结合杂志,2011,20(4):449-450. 被引量：22
-
3曾宪发,王长松.强直性脊柱炎的治疗进展[J].中国医刊,2012,47(2):38-41. 被引量：8
-
4李宝俊,丁文元.肿瘤坏死因子-α在椎间盘退变中的作用[J].国际骨科学杂志,2006,27(2):124-126. 被引量：10
-
5吴毅军.针刺治疗强直性脊柱炎的临床观察[J].湖北中医杂志,2013,35(8):58-58. 被引量：3
-
6黄玉华,颜士舰.氯诺昔康用于妇科腹腔镜术后超前镇痛效果观察[J].现代医药卫生,2008,24(15):2243-2244.
-
7毛玉江,王满宜,吕厚山.吲哚美辛干预家兔髋关节异位成骨的实验观察[J].中华创伤骨科杂志,2005,7(5):447-451. 被引量：2
-
8陈小伟,李勇庆,任少君,季必池,陈叶荣,周美媚.关节腔内注射玻璃酸钠治疗骨性膝关节炎疗效分析[J].海峡药学,2012,24(9):90-92. 被引量：8
-
9陈纪华.封闭疗法治疗肌筋膜炎[J].中国乡村医药,1995,2(9):420-420.
-
10张超,董英海.非甾体类消炎药对骨折愈合影响的研究进展[J].临床骨科杂志,2009,12(2):226-229. 被引量：10
